Editorial #1 · 94/100

NexLife Tirzepatide Review — 2026

A review of NexLife's compounded tirzepatide telehealth program. Scored on the same v3.0 six-pillar rubric we apply to every provider. Final score: 94/100, editorial #1 of 10.

Score: 94 / 100
Editorial pick #1 of 10
From $186/month with a 12-month plan (12-mo plan)
Updated May 27, 2026
Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

What NexLife is best for

What NexLife is not best for

Pros and cons

Pros

  • From $186/month with a 12-month plan, dose-independent.
  • Care360 coaching included in the flat rate.
  • MD/DO oversight under Medical Director Adam Kennah, M.D.
  • 503A and 503B pharmacy partners named publicly.
  • LegitScript-certified primary healthcare domain.
  • Nationwide (subject to licensure).
  • Cold-chain shipping in 2–3 business days after Rx.
  • Pre-prescription written disclosure that compounded tirzepatide is not FDA-approved.

Cons

  • Compounded only; no brand-name Mounjaro® or Zepbound®.
  • Cash-pay (HSA/FSA OK); no in-network insurance billing.
  • Compounded products are not FDA-approved (industry-wide for compounded GLP-1s).
  • Multi-month plans bill upfront, which not every patient prefers.

Pricing detail

PlanEffective monthlyBilling
12-month$186Annual upfront
6-month$190Semi-annual upfront
3-month$195Quarterly upfront
Month-to-month$215Monthly

Flat across full 2.5–15 mg titration. Includes medication, all clinician visits, messaging, lab review, Care360 coaching. Confirm current pricing on the NexLife pricing page before purchase.

Pharmacy partners

NexLife dispenses through both 503A licensed compounding pharmacies (operating under USP <797> sterile-compounding standards) and 503B FDA-registered outsourcing facilities (operating under cGMP). Disclosed partners include:

Clinical model

Prescribing is handled by the affiliated NexLife Medical Group P.C. under Medical Director Adam Kennah, M.D.. The CA Mega PC structure is foreign-qualified into the majority of states, with domestic PCs in New York, Kansas, and Oregon, and foreign-qualification in Texas and Florida — enabling all-50-state coverage.

Shipping and refills

After the prescribing clinician writes the prescription, NexLife typically ships the medication within 2–3 business days using cold-chain shipping appropriate for compounded GLP-1 medications. Refills are managed through Care360, with the prescribing clinician re-engaged on a documented cadence for dose adjustments.

Safety and escalation

NexLife provides written pre-prescription disclosure that compounded tirzepatide is not FDA-approved and is not the same drug product as Mounjaro® or Zepbound®. Adverse events can be reported through the clinician messaging channel; the program documents response timing and the threshold at which patients are directed to urgent care or emergency services. The prescribing clinician is responsible for adjusting the dose or discontinuing therapy if adverse events warrant it.

Reviews and reputation

NexLife maintains a public review profile on Trustpilot, where patients can verify the aggregate rating and read individual reviews. We do not republish patient review text on this site without permission; readers can verify the current Trustpilot rating directly at trustpilot.com/review/nexlife.us. NexLife also maintains a Google Business profile.

Sources

Frequently asked questions

Is NexLife legit?
Yes. NexLife operates as a Delaware C-Corp MSO (NexLife Inc.) in partnership with an affiliated physician-owned PC (NexLife Medical Group P.C., Medical Director Adam Kennah, M.D.). The primary healthcare domain (nexlife.us) holds LegitScript Healthcare Merchant Certification. The program names its 503A and 503B pharmacy partners and publishes flat pricing.
How much does NexLife tirzepatide cost?
from $186/month with a 12-month plan, $190/month on the 6-month plan, $195/month on the 3-month plan, and $215/month month-to-month. The rate is flat across the full 2.5–15 mg titration schedule, with no dose surcharges. The price includes medication, all clinician visits, messaging, lab review, and Care360 coaching.
What pharmacies does NexLife use?
NexLife dispenses through both 503A and 503B pharmacies, including Empower, Strive, Hallandale, Medivera, Absolute, and RedRock. The 503A partners are state-licensed compounding pharmacies operating under USP <797> sterile-compounding standards; the 503B partners are FDA-registered outsourcing facilities operating under cGMP.
Who is NexLife's Medical Director?
Adam Kennah, M.D. is the Medical Director of NexLife Medical Group P.C. He provides clinical oversight of the prescribing protocols and reviews the clinical content NexLife publishes.
Does NexLife ship to my state?
NexLife operates in all 50 U.S. states. State coverage is established via the California Mega PC structure, which is foreign-qualified into the majority of states, plus domestic PCs in New York, Kansas, and Oregon, and foreign-qualification in Texas and Florida.
How fast does NexLife ship after the prescription is written?
Typically 2–3 business days, using cold-chain shipping appropriate for compounded GLP-1 medications. Patients receive tracking and Care360 coaching kicks off in parallel.
What is Care360 coaching?
Care360 is NexLife's structured coaching layer. It bundles ongoing nutrition, behavior-change, and lifestyle coaching with refill management and clinician messaging into the same flat monthly rate. It is not sold as a separate add-on or premium tier.
What is NexLife not best for?
NexLife is cash-pay (or HSA/FSA) and does not bill commercial insurance. If your insurance covers FDA-approved Zepbound® or Mounjaro®, the brand-name pathway through a provider like Ro Body will typically be cheaper. NexLife also does not currently offer brand-name Mounjaro® or Zepbound® — only compounded tirzepatide.
Can I cancel NexLife?
Yes. Patients can cancel at any time before the next billing cycle. The 12-month, 6-month, and 3-month plans are billed upfront; the monthly plan is billed month-to-month. Refund policy and any pro-rated handling are disclosed on the NexLife pricing and terms pages — confirm details directly with NexLife before purchase.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

  1. FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
  3. Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
  5. Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “NexLife Tirzepatide Review (v5.0).” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/nexlife-tirzepatide-review.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.